118 related articles for article (PubMed ID: 26048120)
21. [Economic evaluation of combined therapy in chronic hepatitis C].
Casado MA; Buti M; Fosbrook L; Esteban R
Gastroenterol Hepatol; 2000 Feb; 23 Suppl 1():57-62. PubMed ID: 11968346
[No Abstract] [Full Text] [Related]
22. Providing antiretroviral therapy for HIV infection.
Steinbrook R
N Engl J Med; 2001 Mar; 344(11):844-6. PubMed ID: 11248164
[No Abstract] [Full Text] [Related]
23. Combination therapy in naive patients with chronic hepatitis C: more value for the money.
Koff RS
J Hepatol; 2000 Oct; 33(4):664-6. PubMed ID: 11059875
[No Abstract] [Full Text] [Related]
24. Personalized cost-effectiveness of boceprevir-based triple therapy for untreated patients with genotype 1 chronic hepatitis C.
Petta S; Cabibbo G; Enea M; Macaluso FS; Plaia A; Bruno R; Gasbarrini A; Bruno S; Craxì A; Cammà C;
Dig Liver Dis; 2014 Oct; 46(10):936-42. PubMed ID: 25066806
[TBL] [Abstract][Full Text] [Related]
25. Exploring the costs of a limited public sector antiretroviral treatment programme in South Africa.
Boulle A; Kenyon C; Skordis J; Wood R
S Afr Med J; 2002 Oct; 92(10):811-7. PubMed ID: 12432807
[TBL] [Abstract][Full Text] [Related]
26. [Public health economic aspects of antiretroviral therapy. Can we afford to do less?].
Stoll M; Claes C; Schulte E; Körner T; von der Schulenburg JM; Schmidt R
MMW Fortschr Med; 2000 Mar; 142 Suppl 1():45-9. PubMed ID: 10863311
[TBL] [Abstract][Full Text] [Related]
27. The cost of treatment failure: resource use and costs incurred by hepatitis C virus genotype 1-infected patients who do or do not achieve sustained virological response to therapy.
Backx M; Lewszuk A; White JR; Cole J; Sreedharan A; van Sanden S; Diels J; Lawson A; Neal KR; Wiselka MJ; Ito T; Irving WL
J Viral Hepat; 2014 Mar; 21(3):208-15. PubMed ID: 24438682
[TBL] [Abstract][Full Text] [Related]
28. [Analysis of costs and cost-effectiveness of the preferred treatments by GESIDA/National plan for AIDS for initial antiretroviral therapy in 2012].
Martín-Herrero JE; Parrondo-García J; Rodríguez-Alcántara F
Enferm Infecc Microbiol Clin; 2012 Oct; 30(8):509-10; author reply 511-2. PubMed ID: 22824178
[No Abstract] [Full Text] [Related]
29. Bridging the resource gap: improving value for money in HIV/AIDS treatment.
Soni A; Gupta R
Health Aff (Millwood); 2009; 28(6):1617-28. PubMed ID: 19887403
[TBL] [Abstract][Full Text] [Related]
30. NHS England blames possible legal action for decision not to fund HIV prevention pill.
Hawkes N
BMJ; 2016 Mar; 352():i1708. PubMed ID: 27009291
[No Abstract] [Full Text] [Related]
31. [On the brink of a new era in the treatment of chronic hepatitis C virus infection in Denmark].
Eiset AH; Holm MP; Leutscher PD
Ugeskr Laeger; 2014 Jul; 176(30):. PubMed ID: 25292241
[TBL] [Abstract][Full Text] [Related]
32. Cost-Utility of Access to Care, a National HIV Linkage, Re-engagement and Retention in Care Program.
Maulsby C; Jain KM; Weir BW; Enobun B; Werner M; Riordan M; Holtgrave DR;
AIDS Behav; 2018 Nov; 22(11):3734-3741. PubMed ID: 29302844
[TBL] [Abstract][Full Text] [Related]
33. Economics of chronic hepatitis B and hepatitis C.
Rajendra A; Wong JB
J Hepatol; 2007 Oct; 47(4):608-17. PubMed ID: 17697724
[TBL] [Abstract][Full Text] [Related]
34. The costs of triple-drug anti-HIV therapy for adults in the Americas.
Montaner JS; Hogg RS; Weber AE; Anis AH; O'Shaughnessy MV; Schechter MT
JAMA; 1998 Apr 22-29; 279(16):1263-4. PubMed ID: 9565005
[No Abstract] [Full Text] [Related]
35. [HIV/HCV coinfection. A good chance of recovery also for dually infected patients].
MMW Fortschr Med; 2014 Jun; 156 Suppl 1():7. PubMed ID: 25026843
[No Abstract] [Full Text] [Related]
36. [In process].
Erlhoff J; Huisman F; Mohrenstecher K
Pflege Z; 2016 Jul; 69(7):385-8. PubMed ID: 29414222
[No Abstract] [Full Text] [Related]
37. [Costs of modern treatment of chronic hepatitis C].
Stiefelhagen P; Sarrazin C
Med Monatsschr Pharm; 2015 Sep; 38(9):347-9. PubMed ID: 26731852
[No Abstract] [Full Text] [Related]
38. [Quality of care and health economics in occupationally acquired hepatitis C in German health care workers between 1993 and 2004].
Reiser M; Haverkamp A; Dintsios M; Mölleken C; Krauth C; Pieper W; Schmiegel W
Dtsch Med Wochenschr; 2007 Aug; 132(34-35):1743-7. PubMed ID: 17713882
[TBL] [Abstract][Full Text] [Related]
39. The impact of state policy on the costs of HIV infection.
Goldman DP; Bhattacharya J; Leibowitz AA; Joyce GF; Shapiro MF; Bozzette SA
Med Care Res Rev; 2001 Mar; 58(1):31-53; discussion 54-9. PubMed ID: 11236232
[TBL] [Abstract][Full Text] [Related]
40. [Not Available].
Klinker H
MMW Fortschr Med; 2015 Jun; 157 Suppl 2():36-40. PubMed ID: 26048119
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
